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ABSTRACT: Studies were undertaken to determine whether
extracellular signal regulated kinase (ERK) oscillations regulate
a unique subset of genes in human keratinocytes and
subsequently whether the p38 stress response inhibits ERK
oscillations. A DNA microarray identified many genes that
were unique to ERK oscillations, and network reconstruction
predicted an important role for the mediator complex subunit
1 (MED1) node in mediating ERK oscillation-dependent gene
expression. Increased ERK-dependent phosphorylation of
MED1 was observed in oscillating cells compared to
nonoscillating counterparts as validation. Treatment of
keratinocytes with a p38 inhibitor (SB203580) increased ERK oscillation amplitudes and MED1 and phospho-MED1 protein
levels. Bromate is a probable human carcinogen that activates p38. Bromate inhibited ERK oscillations in human keratinocytes
and JB6 cells and induced an increase in phospho-p38 and a decrease in phospho-MED1 protein levels. Treatment of normal rat
kidney cells and primary salivary gland epithelial cells with bromate decreased phospho-MED1 levels in a reversible fashion upon
treatment with p38 inhibitors (SB202190; SB203580). Our results indicate that oscillatory behavior in the ERK pathway alters
homeostatic gene regulation patterns and that the cellular response to perturbation may manifest differently in oscillating vs
nonoscillating cells.
■ INTRODUCTION
Signaling through the mitogen activated protein kinase
(MAPK) network affects virtually every major aspect of cell
physiology and is among the most intensely studied cell
signaling pathways in biology. Multiple MAPK regulatory
features related to signal strength, signal duration, compart-
mental localization, coordination through scaffolds/inhibitors,
and dynamic behaviors have been characterized.1−5 Four
MAPK branches have been defined and are referenced
according to their terminal kinase (p38, extracellular signal
regulated kinase (ERK), JNK, and ERK5).6 MAPK branches
are frequently associated with opposing cellular programs, such
as p38/JNK regulating differentiation, stress-responsive signal-
ing/apoptosis, and ERK/ERK5 regulating mitogenic signal-
ing.7,8 Exceptions have been observed, such as a role for p38 in
proliferation9,10 or ERK in cell death,11 making it difficult to
rely on measurements of kinase activities for predicting
biological response.
Our group has defined oscillatory behavior in the ERK
pathway,12 and the function of this dynamic behavior in cells
and tissues is currently unknown. ERK oscillations are observed
in primary cell culture and become deregulated with prolonged
passage.13 The mechanisms by which ERK oscillations are
deregulated in vitro remain unclear; however, these observa-
tions suggest that the oscillating phenotype is under-
represented in cell culture models used for toxicological
investigations. ERK oscillations regulate a tumor suppressor
activity that is conserved in vitro/in vivo,14 suggesting that
oscillatory behavior can significantly impact biological out-
comes. Therefore, it is prudent to consider this regulatory
feature in toxicological investigations, and there is a need to
bridge the molecular dynamics observed in vitro with complex
biology in tissues to improve the interpretation of experimental
models used for hazard assessment and risk prediction. ERK
oscillations are measured at the single cell level in vitro, which is
not experimentally tractable in animal models. In contrast,
genes that are uniquely regulated by ERK oscillations could
provide a bridge that can be examined in vivo by standard
molecular/histological methods.
To date, the molecular features regulating canonical ERK
signaling also regulate oscillatory behavior.5,12 Stress-responsive
signaling is known to antagonize the ERK pathway,15 but this
cross-talk has not yet been demonstrated to regulate oscillatory
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behavior and may be of toxicological interest. As a first step
toward advancing our understanding of ERK dynamics in
complex tissues, we have defined gene expression patterns
regulated by ERK oscillations and provide an initial assessment
of regulatory nodes that may mediate oscillation-specific gene
expression that are also targets of stress-responsive signaling.
■ MATERIALS AND METHODS
Cell Culture. hTERT-immortalized normal human keratinocytes
(kindly provided by Dr. Jerry Shay, The University of Texas
Southwestern Medical Center) with and without stable transfection
with an ERK1-green fluorescent protein (ERK-GFP) chimera were
maintained as previously described.16 The parental human keratino-
cyte line was maintained in Keratinocyte Serum Free Medium
(InVitrogen; Carlsbad, CA) supplemented with bovine pituitary
extract and epidermal growth factor (EGF) according to the
manufacturer’s directions. A subclone of the parental human
keratinocyte line that self-regulates persistent and sustained ERK
oscillations via an EGF receptor (EGFR)-dependent mechanism
without the need for the exogenous EGFR ligand was maintained in
keratinocyte serum free medium supplemented with pituitary extract
alone. It is unclear whether this self-maintaining subclone regulates
ERK oscillations via an EGFR autocrine loop or mutant EGFR.
Keratinocytes were subcultured using 0.025% trypsin and 3 volumes of
trypsin neutralizing solution. From this parental keratinocyte cell line,
we subcloned 3 distinct strains (#1−3) that differ in their ability to
regulate ERK oscillations. The characteristics of these strains are
outlined in Figure 1. Normal rat kidney cells (NRK CRL-6509,
proximal tubule in origin) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% antibiotic antimycotic solution (Sigma Chemical, St.
Louis, MO). Cells were seeded in 12-well plates at 150,000 cells/mL
and allowed to grow for 24 h (90% confluence). Cells were then
exposed to 10 μM PD98059 or concentrations of bromate (KBrO3;
Sigma Chemical, St. Loius, MO) ranging from 0.06−0.3 mM for the
indicated time points before being washed and harvested using a
rubber policeman in immunoblot buffer (40 mM Tris [pH 7.5], 1 mM
EDTA, 1 mM ethylene glycol tetraacetic acid (EGTA), 5% NP-40, 1
μM activated orthovanadate). In select experiments, cells were treated
with pharmacological inhibitors of p38 (SB203580, SB202190), JNK
(SP600125), or MEK (PD98059) (Enzo Life Sciences, Farmingdale,
NY). We have previously demonstrated that bromate activates the p38
pathway at concentrations employed in our studies,15,22 and this
toxicant was used to further interrogate p38-dependent antagonism of
ERK signaling.
Isolation and Culture of Primary Salivary Epithelial Cells.
Primary salivary gland epithelial cells were isolated from adult male
Sprague−Dawley rat submaxillary glands. Glands were removed
aseptically; the outer connective tissue was excised followed by
washing in Hank’s balanced salt solution (HBSS) supplemented with
1× antibiotic/antimycotic (Life Technologies 100× antibiotic−
antimycotic solution, Grand Island, NY). Glands were cut into cubes
of approximately 1 mm3 followed by washing 2× in HBSS using
gravity settling. Cubes were then suspended in HBSS supplemented
with collagenase (CLSPA, 150 units/mL) and hyaluronidase (150
units/mL) (Worthington Biochemical Corporation, Lakewood, NJ)
and dissociated for 45 min at 37 °C with gentle rocking. The digests
were passed through a 70 μm nylon mesh, and isolated cells were
collected by centrifugation at 1300 rpm for 5 min. Cell pellets were
resuspended in advanced DMEM:F12 supplemented with 2.5% FBS, 2
mM Glutamax, 100 units/mL penicillin, 100 units/mL streptomycin,
0.25 μg/mL fungizone, and 10 ng/mL epidermal growth factor (EGF).
Cells were subcultured by trypsinization and used at passage 3.
ERK Oscillation Assay. An oscillation assay that monitors
persistent ERK nuclear-cytoplasmic shuttling at the single cell level
was used as described.12,16 Persistent nuclear-cytoplasmic shuttling
requires coordinated regulation by both positive and negative feedback
processes17 and is an appropriate index for long-term monitoring of
ERK activity in live cells. Oscillation characteristics included
amplitude, time period, rise time, and decay time. Two independent
experiments were pooled for statistical analysis (approximately 100
cells). Results from p38 inhibitor studies in pooled experiments were
validated separately at the single cell level as described in Results.
Microarray Analysis. Gene expression patterns using the
Affymetrix system were defined as previously described.14 Tran-
scriptomics for each cell strain was defined for conditions of low vs
high ERK activity. This was accomplished by maintaining strains 1 and
2 in the presence (high ERK activity) or absence (low ERK activity) of
transforming growth factor alpha (TGFα). For strain #3 (self
Figure 1. Human keratinocyte model system. Three independent cell strains were subcloned from an hTERT-immortalized normal human
keratinocyte cell line that had been transduced with an ERK1-GFP chimera to monitor ERK nuclear-cytoplasmic shuttling. Strain #1 shows transient
ERK activation and nuclear translocation following TGFα treatment with no detectable oscillations. Strain #2 displays persistent ERK oscillations
that are dependent on exogenous TGFα and inhibited by mAb 225, indicating dependence on the EGFR. Strain #3 displays spontaneous ERK
oscillations that are inhibited by mAb 225, indicating dependence on the EGFR. The time period is different for ERK oscillations regulated in strain
#1 compared to strain #2.
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regulated ERK oscillations), cells were maintained in the presence of
nonspecific immunoglobulin G (IgG) (high ERK activity) or EGFR
neutralizing antibody (mAb 225; low ERK activity; Figure 1). The
microarray experimental design employed 5 independent biological
replicates (n = 5) for each condition to ensure robust statistical power.
All microarray data used in this study have been deposited into the
Gene Expression Omnibus database under accession number
GSE55823.
Western Blot. Western blot analysis was performed as previously
described.12 Titers for primary and secondary antibodies were 1:3000
and 1:5000, respectively. Antibodies used included mediator complex
subunit 1/phospho-MED1 (MED1/P-MED1) T1457 (abcam, Cam-
bridge, MA), P-p38 (Cell Signaling Technologies, Beverly, MA), actin
(EMD Millipore, Billerica, MA), and ZO-1 (Invitrogen, Camarillo,
CA).
Statistical Analysis. Individual comparisons were made using
Student’s t test or ANOVA with a posthoc Student’s Newman−Keul
test, as appropriate. The p < 0.05 level was accepted as significant.
■ RESULTS
Three independent cell strains have been subcloned from an
hTERT immortalized normal human keratinocyte cell line.
Strain #1 exhibits transient ERK activation induced by TGFα,
without detectable oscillations (Figure 1). Strain #2 exhibits
persistent ERK oscillations that are dependent on stimulation
with exogenous TGFα. Strain #3 exhibits spontaneous ERK
oscillations in the absence of exogenous TGFα. An EGFR
neutralizing antibody (mAb 225)18 fully inhibits ERK
oscillations in strains #2 and #3 (Figure 1), indicating
dependence on the EGFR in both cases. The time period for
ERK oscillations is slightly prolonged in strain #3, as compared
with strain #2, as might be expected for an autocrine process
requiring the shedding of the ligand. However, we cannot
distinguish whether strain #3 is regulating ERK oscillations via
an EGFR autocrine loop or a mutant EGFR based on results
using mAb225 alone. Collectively, all cell strains share the same
genetic background and EGFR-dependent ERK activation,
which is an ideal scenario for direct comparison of groups in a
microarray experiment.
DNA microarray was used to define transcriptomics of the
human keratinocyte cell lines described in Figure 1. Conditions
for high and low ERK activity were defined for each cell strain
as described in Materials and Methods, and gene expression
patterns for the low ERK activity condition were subtracted
from the high ERK activity condition to enrich for ERK-
dependent gene expression patterns. We then defined the genes
that were common or unique to each cell strain from this
enriched data set. As illustrated in the Venn diagram (Figure
2A), we identified 45 genes that are common to the two
oscillation proficient strains (#2 and #3) and are absent in the
oscillation deficient strain (#1). The Metacore annotated
database was used to predict the transcription factor networks
encompassed within the 45 genes common to ERK oscillations
(Figure 2B). Network reconstruction suggests that ERK
oscillations are coupled to transcription factor networks
through the MED1 coactivator and CD44.
Studies were conducted to determine whether an index of
MED1 activation showed differential regulation under oscillat-
ing vs nonoscillating conditions as validation. ERK phosphor-
ylates MED1 on T1457, which increases MED1 stability and
activity,19 and we examined MED1 T1457 phosphorylation
status (P-MED1) by Western blot analysis in cell strains #1−3.
P-MED1 levels were below detection in strains #1 and #2
under serum-starved conditions, and treatment with EGF for
10 min resulted in a dramatic increase in P-MED1 levels
(Figure 3A). At 8 h post-EGF stimulation, cell strain #2
Figure 2. Microarray comparing oscillating vs nonoscillating cell
strains. Panel A: Venn diagram showing subset of genes enriched for
ERK-dependent regulation in oscillating vs nonoscillating cell strains
and overlap between experimental groups. Panel B: Bioinformatics was
used to predict the major transcription factor networks represented by
the 45 genes common to two independent cell strains exhibiting ERK
oscillations. MED1 and CD44 represent regulatory nodes predicted to
couple ERK oscillations to inferred transcription factor networks.
Figure 3. P-MED1 patterns in cell strains 1−3. Panel A: Cell strains #1
and #2 were serum-starved for 24 h, followed by stimulation with 10
ng/mL EGF for 10 min or 8 h. Panel B: Cell strain #3 (spontaneous
ERK oscillations) was treated with IgG, mAb 225, or PD98059 for 60
min, and P-MED1 levels were determined by Western blot. Similar
results were observed in 2 separate experiments.
Chemical Research in Toxicology Article
dx.doi.org/10.1021/tx500085u | Chem. Res. Toxicol. 2014, 27, 1496−15031498
(ligand-induced oscillations) displayed higher P-MED1 levels
compared with that of cell strain #1 (nonoscillating). Cell strain
#3 (spontaneous oscillations) displayed constitutive P-MED1
levels that were reduced by treatment with mAb 225 or ERK
inhibitor (PD98059) for 60 min (Figure 3B). Thus, oscillatory
behavior in the ERK pathway is associated with increased P-
MED1 status at an established ERK-responsive site.
We subsequently considered the interplay between growth-
and stress-responsive signaling on the ERK-MED1 axis. Stress-
responsive p38 signaling can antagonize the ERK pathway,15
and high oxygen tension in vitro can induce tonic stress.20 Thus,
we asked whether p38-dependent antagonism of ERK
oscillations was apparent under standard cell culture conditions.
TGFα-stimulated keratinocytes were treated with DMSO or 1
μM SB203580 (p38 inhibitor), and ERK oscillation character-
istics were quantified. Treatment with SB203580 resulted in a
marked increase in TGFα-dependent ERK oscillation ampli-
tudes but did not alter the time period, rise time, or decay time
(Figure 4A, white bar; rise/decay time not shown). Additional
evidence that was consistent with p38-dependent negative
feedback included a small increase in the number of TGFα-
stimulated cells displaying ERK oscillations (45% of population
for TGFα-stimulated cells → 53% of population in cells treated
with TGFα + SB203580). Treatment of keratinocytes with
vehicle (DMSO) or a JNK inhibitor (100 nM SP600125)21 did
not alter ERK oscillation characteristics in the presence or
absence of TGFα (data not shown). We then confirmed that
SB203580 increased ERK oscillation amplitudes at the single
cell level. ERK oscillations were monitored in TGFα-treated
human keratinocytes for approximately 1 h prior to the addition
of 1 μM SB203580. ERK oscillation amplitudes were clearly
increased at the single cell level following SB203580 treatment,
as compared with the pretreatment time period (Figure 4B),
confirming the effects of the p38 inhibitor on oscillation
amplitudes. In mathematical terms, ERK oscillations are
classified into two categories, termed clean and noisy
oscillations.22 At present, it is unclear whether any biological
difference exists between clean and noisy oscillators, and Figure
4B illustrates that both clean (bottom trace) and noisy (top
trace) oscillators show a comparable response to the p38
inhibitor.
The increase in ERK oscillation amplitude induced by the
p38 inhibitor suggests increased ERK activation under this
condition since this index requires a quantitative increase in
nuclear ERK-GFP protein levels. We next examined nuclear P-
MED1 levels to determine whether the ERK-MED1 axis was
regulated in a similar manner. Human keratinocytes were
treated with SB203580 for 5−10 min, and nuclear P-ERK and
P-MED1 levels were defined by epifluorescence microscopy
following in situ staining with the appropriate antibodies.
SB203580 treatment resulted in a significant increase in nuclear
P-ERK levels (Figure 5A square), which preceded increased
nuclear P-MED1 levels (Figure 5A, circle). P-MED1 and
MED1 protein levels in nuclear extracts were increased
following treatment of human keratinocytes with SB203580
for 20−60 min, while actin levels served as the loading control
(Figure 5B). The increase in P-MED1 protein level induced by
the p38 inhibitor is suppressed by an ERK inhibitor (PD98059)
but not by a JNK inhibitor (SP600125) (Figure 5C). Thus, p38
inhibition enhances the ERK-dependent phosphorylation and
stabilization of MED1.
Bromate is a probable human carcinogen produced as a
disinfection byproduct from the ozonation of water containing
bromide. The stress response to bromate has been carefully
characterized and includes activation of p38.23,24 ERK
oscillations in human keratinocytes and JB6 cells treated with
1 mM bromate were inhibited following bromate treatment
(Figure 6). Western blot analysis demonstrated that 1 mM
bromate increased phospho-p38 (P-p38) and decreased P-
Figure 4. ERK oscillation amplitudes are increased following
treatment with the p38 inhibitor. Panel A: Pooled results from two
independent experiments showing that SB203580 treatment selectively
increases ERK oscillation amplitudes (white bar) but does not alter
other ERK oscillation characteristics (time period is shown by the
black bar; other oscillation characteristics are not shown). Values
represent the mean ± SE. *Significantly different from TGFα-treated
cells, p < 0.05. Panel B: Single cell trace confirming increase in ERK
oscillation amplitude following SB203580 treatment. Traces represent-
ing noisy (top) and clean (bottom) oscillators are shown to illustrate
that oscillation amplitude is increased by SB203580 in both types.
Figure 5. p38 inhibitor increases ERK activation that precedes MED1 phosphorylation. Panel A: Treatment of human keratinocytes with the p38
inhibitor (SB203580) for 5−10 min results in increased nuclear P-ERK levels (square) that precede detection of increased nuclear P-MED1 levels
(circle). Values represent the mean ± SE. *Significantly different from the respective control, p < 0.05. Panel B: Treatment of human keratinocytes
with SB203580 for 10−60 min results in a time-dependent increase in both P-MED1 and MED1 levels. Panel C: The increase in P-MED1 levels
induced by the p38 inhibitor at 60 min can be blocked by cotreatment with the ERK inhibitor (PD98059) but not the JNK inhibitor (SP600125).
Similar results were observed in two separate experiments.
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MED1 protein levels at 60 min in both model systems. Basal P-
p38 levels were clearly detectable in human keratinocytes,
consistent with results illustrated in Figure 4 showing that p38
inhibitor alone increases ERK oscillation amplitudes in human
keratinocytes. We have observed that JB6 cells are highly
sensitive to hydrogen peroxide-mediated toxicity as compared
with other in vitro models we have used (Weber et al.,
unpublished observation). Bromate treatment induced the
accumulation of ERK-GFP in the nucleus immediately
following the cessation of oscillations to a greater extent in
JB6 cells as compared with human keratinocytes. Although the
mechanism for nuclear accumulation is beyond our present
scope, bromate induces toxicity via the generation of an
oxidative stress.23 Oxidative stress inhibits nuclear export
regulated by the CRM1 export protein,25 which is relevant
because CRM1 regulates the export of ERK from the nucleus.12
Thus, it is plausible that oxidative stress may modulate multiple
mechanisms (e.g., p38 and CRM1) capable of inhibiting ERK
oscillations, and the antioxidant status of the cell system may be
an additional variable for consideration. Movies illustrating
ERK oscillations in human keratinocytes and JB6 cells before
and after the addition of bromate can be found in Supporting
Information (S1 and S2).
We attempted to extend our investigation to normal rat
kidney cells (NRK) and primary salivary gland epithelial cells
but met technical limitations that constrained our interpretation
of p38-dependent cross-talk. Specifically, we used our
established retroviral transduction system12 for ERK-GFP
expression in both model systems. NRK cells showed efficient
transduction with ERK-GFP; however, NRK cells rapidly
acquired a malignant phenotype (within 2−3 passages)
characterized by a stellate morphology and loose adherence
to tissue culture plates (data not shown). Safety protocols
dictate that cells cannot be removed from the virus laboratory
until after 3 passages, and the NRK ERK-GFP cells we were
able to examine under this condition did not display ERK
oscillations in response to EGF treatment (data not shown).
We have shown that JB6 cells transformed to a malignant
phenotype by phorbol ester treatment lose the ability to
regulate oscillatory behavior;12 therefore, the lack of oscillations
in NRK cells are difficult to interpret because the transformed
phenotype may inhibit this dynamic behavior. Primary salivary
gland epithelial cells were also examined for comparison with
immortalized cell line responses; however, the primary cells
were difficult to transduce, and we were unable to generate a
stable model system for analysis.
Although the status of ERK oscillations remains unclear in
NRK and salivary epithelial model systems, we believe that the
antagonistic cross-talk between p38 and the ERK pathways is
relevant to both canonical and dynamic signaling features and
used these models to further investigate the ERK-MED1 axis.
P-MED1 levels are detected in NRK cells and inhibited by 10
μM PD98059 (Figure 7A), indicating that ERK-dependent
regulation of MED1 was conserved in this model. Treatment of
NRK cells with 0.06−0.3 mM bromate for 1 h reduced P-
MED1 levels (Figure 7B), consistent with the activation of p38
by bromate in NRK cells as previously established.14,22 P-
MED1 levels remained depressed in bromate-treated cells at 24
h (data not shown). NRK cells were then treated with 0.06 mM
bromate with or without pretreatment with a p38 inhibitor (10
μM SB202190). Bromate treatment reduced P-MED1 levels,
and this effect was inhibited by SB202190 (Figure 7C and D).
Salivary gland epithelial cells afforded a comparison of the
ERK-MED1 axis in a primary cell system. Salivary epithelial
cells grow as epithelial islands and show localization of the tight
junction protein ZO-1 at points of cell−cell contact (Figure
8A). Treatment of salivary epithelial cells with 1 mM bromate
for 60 min reduced P-MED1 levels, and this effect was inhibited
by the p38 inhibitor SB203580 (Figure 8B and C).
■ DISCUSSION
ERK oscillations represent a new regulatory mode in the ERK
pathway5,12 whose biological function remains unclear. The
Figure 6. Bromate inhibits the ERK-MED1 axis in human and murine
model systems displaying ERK oscillations. ERK oscillations induced
by TGFα (human keratinocytes) or bFGF (JB6 cells) were monitored
for several hours to demonstrate sustained regulation followed by
treatment with 1 mM bromate. Following bromate treatment,
oscillations were observed to cease in both model systems. Bromate
treatment induced an increase in P-p38 and decrease in P-MED1
protein levels as detected by Western blot. Similar results were
observed in two separate experiments.
Figure 7. Bromate decreases P-MED1 levels in NRK cells. Panel A:
Inhibition of MED1 phosphorylation by the ERK inhibitor
(PD98059), confirming ERK-dependent regulation. Panel B: Treat-
ment of NRK cells with 0.06−0.3 mM bromate for 1 h results in a
dose-dependent decrease in P-MED1 levels. Decreased P-MED1 levels
induced by bromate were observed in three separate experiments.
Panels C and D: P-MED1 profile for NRK cells treated with bromate
with or without pretreatment with SB202190 and quantified values.
Results shown in panels C and D are for the 1 h time point, and similar
results were observed at 3 and 24 h time points (data not shown).
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results of the present study advance our understanding of ERK
oscillations through the identification of unique gene expression
patterns that can be used to infer possible biological function.
The sensitivity of MED1 phosphorylation status to stress-
responsive signaling raises the possibility that MED1 may
represent a transcriptional node for signal integration that is
relevant to both canonical and dynamic ERK signaling.
ERK phosphorylates MED1 on T1032/T1457, which imparts
two distinct functions: (1) it stimulates MED1 transcriptional
activity, and (2) it increases the stability and half-life of
MED1.19 Therefore, the activation of MED1 by ERK is
established, and what remains to be determined is how
oscillatory behavior uniquely impacts transcriptional regulation
through the MED1 node. MED1 regulates the activity of a
battery of transcription factors;26−30 therefore, sustained MED1
activation by ERK oscillations could impact a broad transcrip-
tional program. The stabilization of MED1 protein levels by
ERK oscillations might result in the development of a MED1
gradient (Figure 3A), and future studies will determine the
relationship between MED1 protein and ERK activity levels.
Molecular gradients associated with pathways exhibiting
oscillatory behavior have been documented,31,32 and morph-
ogens demonstrate the importance of gradients as a regulatory
mode in biology.33,34 Theoretically, an increase in MED1
stoichiometry is expected to permit interaction of MED1 with
low abundance transcription factors following saturation of
MED1 binding sites on high abundance transcription factors.
Other mechanisms are possible, and additional studies focused
on the MED1 node are warranted.
p38 antagonizes canonical ERK signaling,15 and it was
prudent to demonstrate that this antagonism extended to ERK
oscillations and the ERK-MED1 axis (Figures 6−8). Prior work
by Wiley’s group22 has demonstrated an important balance
between positive and negative feedback loops in regulating
oscillatory behavior. In fact, they demonstrated that treatment
of cells with a phosphatase inhibitor alone in the absence of
growth factor was sufficient to induce ERK oscillations. p38-
dependent antagonism of ERK oscillations illustrates another
example of negative feedback that is relevant to toxicological
investigations in light of the broad association of p38 with
stress-responsive signaling. Because ERK oscillations regulate a
unique subset of genes, these observations raise the possibility
that antagonistic signaling by p38 might manifest differently in
cells displaying transient versus dynamic ERK signaling
behaviors.
Bromate was chosen as a test agent because it is a probable
human carcinogen that activates p38 via the generation of
oxidative stress.23,24 We have previously shown that reactive
oxygen species and ionizing radiation inhibit ERK oscilla-
tions;13 therefore, the inhibition of ERK oscillations by bromate
is consistent with our previous observations. Prior studies have
demonstrated that a bolus dose of hydrogen peroxide inhibits
ERK oscillations and induces ERK accumulation in the nucleus,
while a low dose of ionizing radiation inhibits ERK oscillations
without nuclear ERK accumulation.13 Bromate at a high dose
(1 mM) inhibits ERK oscillations in association with both p38
activation and nuclear accumulation of ERK in JB6 cells (Figure
6). Thus, it appears that multiple mechanisms can contribute to
the inhibition of ERK oscillations and that the p38 stress
response may be activated at lower doses of free radicals,
relative to other possible mechanisms, such as the inhibition of
CRM1-dependent nuclear export. This may provide a useful
gauge for interpreting the level of oxygen free radicals produced
by toxicants in vivo, based on a comparison of p38 activation,
the nuclear accumulation of ERK/CRM1, and target
oscillation-specific gene expression patterns for oscillation
positive cell types.
In the context of carcinogenesis, bFGF-dependent ERK
oscillations regulate tumor suppressor activity in JB6 cells that
is conserved in mouse skin carcinogenesis.14 We have defined
gene expression patterns that are unique to bFGF in JB6 cells
and not associated with the fully transformed JB6 phenotype
(RT101 cells).14 We have analyzed this data set and identified
tumor suppressors unique to bFGF-dependent ERK oscillations
(lysyl oxidase,35 ≈7-fold ↑; aspartoacylase 2,36 ≈9-fold ↑;
insulin-like growth factor binding protein 5,37 ≈9-fold ↑; and
scavenger receptor class A, member 5,38 ≈7-fold ↑). In human
keratinocytes (Figure 2B), ERK oscillations were uniquely
associated with increased tumor suppressor mRNA expression,
including PDCD6,39 CD44,40 WNT7A,41 HOPX,42 WNT5A,43
and others. Thus, the regulation of multiple tumor suppressor
genes was a common function of ERK oscillations in murine
and human model systems. Antagonism of ERK oscillations
might decrease tumor suppressor activity, which has obvious
implications for increasing cancer risk.
In considering the ERK-MED1 axis, MED1 is known to form
a complex with tumor suppressor genes such as BRCA1.44
Alternatively, MED1 is a transcriptional coactivator for several
nuclear hormone receptors, including members of the vitamin
D and retinoic acid families.45 Our experimental model systems
are derived from skin, and both the vitamin D receptor46 and
retinoid receptors47−49 are implicated as tumor suppressors in
skin. Therefore, increasing MED1 transcriptional coactivation is
expected to increase tumor suppressor activities mediated by
vitamin D and retinoic acid pathways. In the murine model
system where bFGF-dependent ERK oscillations directly inhibit
the cell transformation response,14 retinoid X receptor alpha
mRNA expression is increased (2-fold), which could further
sensitize retinoid-mediated tumor suppression. In human
keratinocytes, retinoid receptor beta (RXRB) mRNA showed
decreased expression with ERK oscillations, and a RXRB-causal
network in human cancer has been hypothesized by
independent investigators.50 Therefore, retinoid signaling is a
Figure 8. Bromate decreases P-MED1 levels in primary salivary
epithelial cells. Panel A: Primary salivary epithelial cells grow as islands
and express significant levels of the ZO-1 tight junction protein
localized to points of cell−cell contact. Panels B and C: P-MED1
profile for salivary epithelial cells treated with 1 mM bromate with or
without pretreatment with SB203580 and quantified values. Similar
results were observed in 2 separate experiments.
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common theme in microarray data sets defining oscillation-
specific gene expression.
In summary, we have demonstrated that oscillatory behavior
in the ERK pathway couples to the regulation of a unique
subset of genes, including many tumor suppressor genes.
Network reconstruction suggests that ERK oscillations are
decoded into a transcriptional response, at least in part, through
MED1 whose activation is antagonized by p38. Our results
indicate that oscillatory behavior in the ERK pathway can alter
homeostatic gene regulation patterns and that the cellular




Two movies illustrating normal human keratinocytes treated
with 10 ng/mL TGFα with cells displaying observable
oscillations (movie S1) and JB6 cells treated with 10 ng/mL
bFGF with cells displaying observable oscillations (Movie S2).
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